GHRH is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-11. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
Anaroids (アーナロイド, Ānaroido): Asteroid-themed androids that wield blasters and swords. The Anaroids are voiced by Katsumi Shiono (塩野 勝美, Shiono Katsumi) and Yuuki Anai (穴井 勇輝, Anai Yūki). Batsuroids (バーツロイド, Bātsuroido): Planet-themed androids that lead the Anaroids and wield hand-mounted guns and, later, swords. Throughout the series, the Batsuroids pilot Kaijuki such as the chest of drawers-themed Super Kaijuki (超巨大怪重機, Chōkyodai Kaijūki) Big Drawer (ビグドローワー, Bigu Dorōwā), which is capable of storing buildings, the flight-capable Hunter Jet 2 (ハンタージェット2, Hantā Jetto Tsū), the angel-themed Megaroria (メガロリア), and the knight-themed Knight Chaser (ナイトチェイサー, Naito Cheisā) before being destroyed by Deka Base Robo, confiscated by the Dekarangers for use in a sting operation, destroyed by Deka Bike Robo, and destroyed by Super Dekaranger Robo respectively. The Batsuroids are voiced by Katsumi Shiono and Yuuki Anai. Igaroids (イーガロイド, Īgaroido): Star-themed androids that are able to speak human languages, lead the Anaroids and Batsuroids, and primarily wield swords that allow them to perform the Cross Burst (クロスバースト, Kurosu Bāsuto) attack. The Igaroids are voiced by Kazuya Nakai (中井 和哉, Nakai Kazuya).
The ascent led through forests of chestnut, laurels, and heaths, and onto higher, barren volcanic plains such as Llano del Retama, where vegetation diminished and only shrubs and wildlife remained. At Estancia de los Ingleses, a traditional rest point at about 8,000 feet (2,400 m), the group endured a cold, windy night before continuing the climb at 3 a.m. on 22 June 1799. They crossed the Malpays, an area of broken lava and little vegetation, and reached the summit at 8 a.m. At the peak, the party observed the structure of the volcano, measured ground temperatures, and collected air samples. The elliptical crater showed no recent eruptions inside, but the volcano remained active, with recent lava flows and geothermal activity. The summit provided panoramic views of the surrounding islands and the diverse ecological zones descending from the peak, which Humboldt recorded in a sketch. He noted five distinct vegetation zones, from grasses at the summit to cultivated tropical and temperate plants near the coast. The descent took the party back through the varying ecological regions. Humboldt made broader geological observations, considering questions about the structure and origins of volcanoes and the laws governing geological phenomena. The round trip from La Orotava to the summit and back lasted twenty-one hours. The Pizarro’s departure was delayed until 24 or 25 June 1799 due to the presence of an English squadron, allowing Humboldt and Bonpland additional time to explore the island’s surroundings.
As described above, macrophages play a key role in removing dying or dead cells and cellular debris. Erythrocytes have a lifespan on average of 120 days and so are constantly being destroyed by macrophages in the spleen and liver. Macrophages will also engulf macromolecules, and so play a key role in the pharmacokinetics of parenteral irons. The iron that is released from the haemoglobin is either stored internally in ferritin or is released into the circulation via ferroportin. In cases where systemic iron levels are raised, or where inflammation is present, raised levels of hepcidin act on macrophage ferroportin channels, leading to iron remaining within the macrophages.
Sources: en.wikipedia.org
"Dude, people just don't want to eat pink slime". MarketWatch. Retrieved April 4, 2012. Greene, Joel L. (April 6, 2012). "Lean Finely Textured Beef: The 'Pink Slime' Controversy". Congressional Research Service. Retrieved March 2016. Gruley, Bryan; Campbell, Elizabeth (April 12, 2012). "'Pink Slime' Furor Means Disaster For U.S. Meat Innovator". Bloomberg. Retrieved July 19, 2012. Glen, Barb (June 22, 2012). "Lessons learned for Cargill in pink slime's 'ick' factor". The Western Producer. Retrieved July 18, 2012. "Pink slime saga boosts beef exports". The Australian. June 19, 2012. Retrieved July 18, 2012. Wessler, Brett (June 25, 2012). "Former BPI employee plans lawsuit for pink slime frenzy". Drovers/CattleNetwork Magazine. Archived from the original on May 1, 2013. Retrieved July 18, 2012. Siefer, Ted (July 10, 2012). "School board votes to donate 'pink slime'". New Hampshire Union Leader. Archived from the original on June 17, 2013. Retrieved July 18, 2012. Stebbins, Christine (July 12, 2012). "Cargill buys AFA Foods Fort Worth beef processing plant". Reuters. Retrieved October 10, 2013. Engber, Daniel (October 25, 2012). "The Sliming". Slate. Retrieved March 25, 2016. Russell, Joyce (June 19, 2014). "'Pink Slime' Is Making A Comeback. Do You Have A Beef With That?". NPR. Retrieved March 24, 2016. Isidore, Chris (August 13, 2014). "'Pink slime' is back and headed for your burger". CNN Money. Archived from the original on August 16, 2014. Retrieved March 25, 2016. Sanburn, Josh (August 26, 2014). "'Pink Slime' Ground Meat is Back". Time. Retrieved March 24, 2016.
== Epidemiology == BPD has a point prevalence of 1.6% and a lifetime prevalence of 5.9% of the global population. Within clinical settings, the occurrence of BPD is 6.4% among urban primary care patients, 9.3% among psychiatric outpatients, and approximately 20% among psychiatric inpatients. Utilization of healthcare resources by individuals with BPD is high. Up to half may show significant improvement in their condition, resulting in ineligibility for diagnosis of BPD, following a ten-year period with appropriate treatment. Regarding gender distribution, women are diagnosed with BPD three times more frequently than men in clinical environments. Nonetheless, epidemiological research in the United States indicates no significant gender difference in the lifetime prevalence of BPD within the general population. Feminist scholars argue that the diagnosis is disproportionately applied to women, particularly survivors of childhood sexual abuse, and that it pathologizes the understandable emotional and relational responses to gendered violence. The relationship between BPD and ethnicity continues to be ambiguous, with divergent findings reported in the United States. The overall prevalence of BPD in the U.S. prison population is thought to be 17%. Sexual minorities (i.e., lesbian, gay, bisexual) are up to 3.82 times more likely to be diagnosed with BPD and gender minorities (i.e., transgender and gender diverse) are up to 4.05 times more likely to be diagnosed.
One of the 4th Panzer Army commanders, Erich Hoepner, was executed for his role in the 20 July plot. Following the end of the war, one of the 4th Panzer Army former commanders, Hermann Hoth, was tried in the High Command Trial, one of the Subsequent Nuremberg Trials. Explaining his harsh measures against Jews and other civilians, he claimed that "it was a matter of common knowledge in Russia that it was the Jew in particular who participated in a very large extent in sabotage, espionage, etc." Hoth was found guilty of war crimes and crimes against humanity. On 27 October 1948, he was sentenced to 15 years in prison. In January 1951, the sentence was reviewed with no changes. Hoth was released on parole in 1954; his sentence was reduced to time served in 1957. None of the other commanders ever faced charges.
MRI uses powerful magnets and can therefore cause magnetic materials to move at great speeds, posing a projectile risk, and may cause fatal accidents. However, as millions of MRIs are performed globally each year, fatalities are extremely rare. MRI machines can produce loud noise, up to 120 dB(A). This can cause hearing loss, tinnitus and hyperacusis, so appropriate hearing protection is essential for anyone inside the MRI scanner room during the examination.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.